US 12,152,070 B2
Medicinal composition containing monoclonal antibody or antibody fab fragment thereof, and use thereof
Ju-Ming Wang, Tainan (CN); I-Chen Lee, Tainan (CN); Yu-Wei Hsiao, Tainan (CN); Jhih-Ying Chi, New Taipei (CN); Jyun-yi Du, Tainan (CN); Hsin-Yin Liang, Tainan (CN); Chao-chun Cheng, Tainan (CN); Chiung-Yuan Ko, Kaohsiung (CN); Feng-Wei Chen, Kaohsiung (CN); and Jhih-Yun Liu, Chiayi County (CN)
Assigned to Ohealth Biopharmaceutical (Suzhou) Co., Ltd., Suzhou (CN)
Appl. No. 17/274,960
Filed by Ohealth Biopharmaceutical (Suzhou) Co., Ltd., Suzhou (CN)
PCT Filed Sep. 13, 2019, PCT No. PCT/CN2019/105824
§ 371(c)(1), (2) Date Mar. 10, 2021,
PCT Pub. No. WO2020/052675, PCT Pub. Date Mar. 19, 2020.
Claims priority of provisional application 62/867,244, filed on Jun. 27, 2019.
Claims priority of application No. PCT/CN2018/105733 (WO), filed on Sep. 14, 2018; and application No. PCT/CN2018/106144 (WO), filed on Sep. 18, 2018.
Prior Publication US 2022/0119507 A1, Apr. 21, 2022
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01); C07K 16/18 (2006.01); G01N 33/577 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/18 (2013.01) [A61P 35/00 (2018.01); G01N 33/577 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/34 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 21 Claims
 
1. An anti-PTX3 monoclonal antibody or antigen-binding fragment thereof comprising
a heavy chain variable (VH) domain comprising a CDR1 having an amino acid sequence listed as SEQ ID NO: 18, a CDR2 having an amino acid sequence listed as SEQ ID NO: 19 and a CDR3 having an amino acid sequence listed as SEQ ID NO: 21, and a light chain variable (VL) domain comprising a CDR1 having an amino acid sequences listed as SEQ ID NO: 22, a CDR2 having an amino acid sequence listed as SEQ ID NO: 23 and a CDR3 having an amino acid sequence listed as SEQ ID NO: 25; or
a heavy chain variable (VH) domain comprising a CDR1 having an amino acid sequence listed as SEQ ID NO: 18, a CDR2 having an amino acid sequence listed as SEQ ID NO: 20 and a CDR3 having an amino acid sequence listed as SEQ ID NO: 21, and a light chain variable (VL) domain comprising a CDR1 having an amino acid sequence listed as SEQ ID NO: 22, a CDR2 having an amino acid sequence listed as SEQ ID NO: 23 and a CDR3 having an amino acid sequence listed as SEQ ID NO: 24; or
a VH domain comprising a CDR1 having an amino acid sequence encoded by a nucleic acid sequence listed as SEQ ID NO: 26, a CDR2 having an amino acid sequence encoded by a nucleic acid sequence listed as SEQ ID NO:27 and a CDR3 having an amino acid sequence encoded by a nucleic acid sequence listed as SEQ ID NO:29, and a VL domain comprising a CDR1 having an amino acid sequence encoded by a nucleic acid sequence listed as SEQ ID NO: 30, a CDR2 having an amino acid sequence encoded by a nucleic acid sequence listed as SEQ ID NO: 31 and a CDR3 having an amino acid sequence encoded by a nucleic acid sequence listed as SEQ ID NO:32; or
a VH domain comprising a CDR1 having an amino acid sequence encoded by a nucleic acid sequence listed as SEQ ID NO: 26, a CDR2 having an amino acid sequence encoded by a nucleic acid sequence listed as SEQ ID NO:28 and a CDR3 having an amino acid sequence encoded by a nucleic acid sequence listed as SEQ ID NO:29, and a VL domain comprising a CDR1 having an amino acid sequence encoded by a nucleic acid sequence listed as SEQ ID NO: 30, a CDR2 having an amino acid sequence encoded by a nucleic acid sequence listed as SEQ ID NO:31 and a CDR3 having an amino acid sequence encoded by a nucleic acid sequence listed as SEQ ID NO:33; or
a VH domain comprising an amino acid sequence listed as SEQ ID NO: 34, and a VL domain comprising an amino acid sequence listed as SEQ ID NO: 36; or
a VH domain comprising an amino acid sequence listed as SEQ ID NO: 35, and a VL domain comprising an amino acid sequence listed as SEQ ID NO: 37; or
a VH domain comprising an amino acid sequence encoded by a nucleic acid sequence listed as SEQ ID NO: 38, and a VL domain comprising an amino acid sequence encoded by a nucleic acid sequence listed as SEQ ID NO: 41; or
a VH domain comprising an amino acid sequence encoded by a nucleic acid sequence listed as SEQ ID NO: 39, and a VL domain comprising an amino acid sequence encoded by a nucleic acid sequence listed as SEQ ID NO: 40.